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Tumor-associated macrophages Due to the negative charge, the bromine ion did not appear in the spectrum, and the counter ion peak was observed at 874.4 (C49H50NO12P + ). The M-1 peak at 873.4 was strong compared to the molecular ion peak, which is likely a result of loss of a hydrogen radical from either the acetal group or one of the benzyl groups in M + . (c) Zeta potential measurements of Dox and Dox-TPP solutions (40 µg mL -1 ). , which primarily targets nuclear DNA, is one of the most widely used and potent Food and Drug Administration (FDA)-approved broad-spectrum chemotherapeutic drugs. However, the antitumor property of Dox is often diminished by development of multidrug resistance (MDR) phenotypes in cancer cells. 8, 9 Strategies that alter the intracellular distribution of Dox can overcome MDR, thereby increasing the drug's therapeutic efficacy. For instance, conjugating Dox to the mitochondria-specific lipophilic triphenylphosphonium (TPP) cation results in mitochondrial targeting. 1 Upon accumulation in mitochondria, Dox-TPP damages mitochondrial DNA, which lacks the efficient repair mechanisms of nuclear DNA. This, in turn, leads to mitochondrial dysfunction and inhibition of ATP production. 1 Since mitochondrial metabolism and ATP-dependent drug efflux are critical for the survival of drug-resistant cells, 10 mitochondria-targeting enables Dox-TPP to overcome MDR in cancer cells.
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Supplementary Note 2
Cancer cells exhibit persistently high levels of reactive oxygen species (ROS) due to the presence of oncogenic mutations that promote aberrant metabolism and protein translation. 11 Since high levels of ROS can damage macromolecules, inactivate enzymes, and trigger senescence and apoptosis, cancer cells counteract the detrimental effects of ROS by producing elevated levels of antioxidant molecules, such as the tripeptide glutathione (GSH; γ-glutamyl-cysteinyl-glycine). 11 Cellular GSH is primarily localized to the cytosol, mitochondria, endoplasmic reticulum and nucleus, and intracellular concentrations of the antioxidant are orders of magnitude higher than those in extracellular fluids. 12 Moreover, studies have reported several fold higher cytosolic levels of GSH in tumors cells compared to healthy cells. 13, 14 A possible explanation for the observed GSH-mediated cargo release from the BSA-PLGA NPs is that the high binding affinity of GSH to BSA leads to formation of stable GSH-BSA complexes 15 on the NP surface, which destabilize the BSA shell. Another possibility is that the crosslinked BSA shell is further stabilized by disulfide bond formation between the exposed Cys34 of adjacent BSA molecules 16 brought into close proximity by crosslinking. GSH would reduce the BSA-BSA disulfide bonds, thereby weakening the BSA shell.
The highly soluble acidity-triggered rational membrane (ATRAM) peptide interacts with lipid membranes in a pH-dependent manner: at physiological or basic pH, ATRAM binds weakly to the membrane surface in a largely unstructured conformation, whereas under acidic conditions protonation of ATRAM's glutamic acid residues increases the overall hydrophobicity of the peptide and leads to its insertion into lipid bilayers as a transmembrane α-helix. 17, 18 The pKa values of ionizable groups in proteins are highly dependent on the environment: for the glutamic acid side-chain, this value ranges from ∼4.0 in solution to > 8.0 in hydrophobic environments. 19, 20 Importantly, the measured membrane insertion pKa of ATRAM is 6.5, 17, 21, 22 This makes ATRAM ideal for targeting the NPs to cancer cells that reside within the acidic microenvironment of solid tumors. 14, 23 
Supplementary Note 4
Tumor-associated macrophages play an important role in cancer survival, proliferation and metastasis. 24 To probe the possible interactions of ATRAM-BSA-PLGA NPs with macrophages within the tumor microenvironment, we attempted to measure the cellular uptake and cytotoxicity of the Dox-TPP loaded NPs in THP-1 cells at pH 6.5. Unfortunately, these experiments were largely unsuccessful due to poor growth of the cells at low pH. Examination of the morphology under the microscope revealed extensive cell damage/death. Moreover, the MTS response of these cells showed significant variability between experiments (and even between different control samples/wells in the same experiment), reflecting the uncontrolled effects of low pH on the cells. Thus, we are unable to comment on the potential interactions between the NPs and tumor-associated macrophages. However, since the vast majority of immune cells (including macrophages) encountered will be in circulation (i.e. at physiological pH), 25, 26 the data presented in Figure 7 represents the most relevant condition for assessing the tumor-targeting capabilities of the ATRAM-BSA-PLGA NPs.
